Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis

  • Martín-Granado, Víctor
  • Ortiz-Rivero, Sara
  • Carmona, Rita
  • Gutiérrez-Herrero, Sara
  • Barrera, Mario
  • San-Segundo, Laura
  • Sequera, Celia
  • Perdiguero, Pedro
  • Lozano, Francisco S.
  • Martin-Herrero, Francisco
  • González-Porras, José R.
  • Muñoz-Chápuli, Ramón
  • Porras, Almudena
  • Guerrero Arroyo, María del Carmen
Previous observations indicated that C3G (RAPGEF1) promotes a-granule release, evidenced by the increase in P-selectin exposure on the platelet surface following its activation. The goal of the present study is to further characterize the potential function of C3G as a modulator of the platelet releasate and its implication in the regulation of angiogenesis. Proteomic analysis revealed a decreased secretion of anti-angiogenic factors from activated transgenic C3G and C3GΔCat platelets. Accordingly, the secretome from both transgenic platelets had an overall pro-angiogenic effect as evidenced by an in vitro capillary-tube formation assay with HUVECs (human umbilical vein endothelial cells) and by two in vivo models of heterotopic tumor growth. In addition, transgenic C3G expression in platelets greatly increased mouse melanoma cells metastasis. Moreover, immunofluorescence microscopy showed that the pro-angiogenic factors VEGF and bFGF were partially retained into a-granules in thrombin- and ADP-activated mouse platelets from both, C3G and C3GΔCat transgenic mice. The observed interaction between C3G and Vesicle-associated membrane protein (Vamp)-7 could explain these results. Concomitantly, increased platelet spreading in both transgenic platelets upon thrombin activation supports this novel function of C3G in a-granule exocytosis. Collectively, our data point out to the co-existence of Rap1GEF-dependent and independent mechanisms mediating C3G effects on platelet secretion, which regulates pathological angiogenesis in tumors and other contexts. The results herein support an important role for platelet C3G in angiogenesis and metastasis., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness [SAF2013-48210-C2-1-R and SAF2016-76588-C2-2-R to CG, SAF2013-48210-C2-2-R and SAF2016-76588-C2-1-R to AP], by two grants from the Council of Education of Junta de Castilla y León, Spain [SA157A12-1 and SA017U16 to CG] and by a grant from the Council of Health of Junta de Castilla y León, Spain [GRS 991/A/14 to FMH]. All funding was cosponsored by the European FEDER Program. VM-G was supported by Dr. Moraza Foundation PhD fellowship. SG-H and CS are recipients of fellowships from the Salamanca University and the Complutense University, respectively, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G contributes to platelet activation and aggregation by regulating major signaling pathways

  • Gutiérrez-Herrero, Sara
  • Fernández-Infante, Cristina
  • Hernández-Cano, Luis
  • Ortiz-Rivero, Sara
  • Guijas, Carlos
  • Martín-Granado, Víctor
  • González-Porras, José R.
  • Balsinde, Jesús
  • Porras, Almudena
  • Guerrero Arroyo, María del Carmen
C3G is a GEF (guanine nucleotide exchange factor) for Rap GTPases, among which the isoform Rap1b is an essential protein in platelet biology. Using transgenic mouse models with platelet-specific overexpression of C3G or mutant C3GΔCat, we have unveiled a new function of C3G in regulating the hemostatic function of platelets through its participation in the thrombin-PKC-Rap1b pathway. C3G also plays important roles in angiogenesis, tumor growth, and metastasis through its regulation of the platelet secretome. In addition, C3G contributes to megakaryopoiesis and thrombopoiesis. Here, we used a platelet-specific C3G-KO mouse model to further support the role of C3G in hemostasis. C3G-KO platelets showed a significant delay in platelet activation and aggregation as a consequence of the defective activation of Rap1, which resulted in decreased thrombus formation in vivo. Additionally, we explored the contribution of C3G-Rap1b to platelet signaling pathways triggered by thrombin, PMA or ADP, in the referenced transgenic mouse model, through the use of a battery of specific inhibitors. We found that platelet C3G is phosphorylated at Tyr504 by a mechanism involving PKC-Src. This phosphorylation was shown to be positively regulated by ERKs through their inhibition of the tyrosine phosphatase Shp2. Moreover, C3G participates in the ADP-P2Y12-PI3K-Rap1b pathway and is a mediator of thrombin-TXA2 activities. However, it inhibits the synthesis of TXA2 through cPLA2 regulation. Taken together, our data reveal the critical role of C3G in the main pathways leading to platelet activation and aggregation through the regulation of Rap1b., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness [SAF2013-48210-C2-1-R and SAF2016-76588-C2-2-R to C. Guerrero, SAF2013-48210-C2-2-R and SAF2016-76588-C2-1-R to A.P.] and by two grants from the Council of Education of Junta de Castilla y León, Spain [SA157A12-1 and SA017U16 to C. Guerrero]. All funding was cosponsored by the European FEDER Program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation

  • Sequera, Celia
  • Bragado, Paloma
  • Manzano Figueroa, Sara
  • Arechederra, María
  • Richelme, Sylvie
  • Gutiérrez-Uzquiza, Álvaro
  • Sánchez, Aranzazu
  • Maina, Flavio
  • Guerrero Arroyo, María del Carmen
  • Porras, Almudena
© 2020 by the authors., The complexity of hepatocellular carcinoma (HCC) challenges the identification of disease-relevant signals. C3G, a guanine nucleotide exchange factor for Rap and other Ras proteins, plays a dual role in cancer acting as either a tumor suppressor or promoter depending on tumor type and stage. The potential relevance of C3G upregulation in HCC patients suggested by database analysis remains unknown. We have explored C3G function in HCC and the underlying mechanisms using public patient data and in vitro and in vivo human and mouse HCC models. We found that C3G is highly expressed in progenitor cells and neonatal hepatocytes, whilst being down-regulated in adult hepatocytes and re-expressed in human HCC patients, mouse HCC models and HCC cell lines. Moreover, high C3G mRNA levels correlate with tumor progression and a lower patient survival rate. C3G expression appears to be tightly modulated within the HCC program, influencing distinct cell biological properties. Hence, high C3G expression levels are necessary for cell tumorigenic properties, as illustrated by reduced colony formation in anchorage-dependent and -independent growth assays induced by permanent C3G silencing using shRNAs. Additionally, we demonstrate that C3G down-regulation interferes with primary HCC tumor formation in xenograft assays, increasing apoptosis and decreasing proliferation. In vitro assays also revealed that C3G down-regulation enhances the pro-migratory, invasive and metastatic properties of HCC cells through an epithelial-mesenchymal switch that favors the acquisition of a more mesenchymal phenotype. Consistently, a low C3G expression in HCC cells correlates with lung metastasis formation in mice. However, the subsequent restoration of C3G levels is associated with metastatic growth. Mechanistically, C3G down-regulation severely impairs HGF/MET signaling activation in HCC cells. Collectively, our results indicate that C3G is a key player in HCC. C3G promotes tumor growth and progression, and the modulation of its levels is essential to ensure distinct biological features of HCC cells throughout the oncogenic program. Furthermore, C3G requirement for HGF/MET signaling full activation provides mechanistic data on how it works, pointing out the relevance of assessing whether high C3G levels could identify HCC responders to MET inhibitors, This work was funded by grants from the Spanish Ministry of Economy and Competitiveness [SAF2013-48210-C2-2-R and SAF2016-76588-C2-1-R to AP; and SAF2013-48210-C2-1-R and SAF2016-76588-C2-2-R to CG], and by two grants from the Council of Education of Junta de Castilla y León, Spain [SA157A12-1 and SA017U16 to CG]. All funding was cosponsored by the European FEDER Program. CS was supported by a fellowship from Complutense University from Madrid and a short-term FEBS’ fellowship. S.M. is a recipient of a FPU fellowship from Spanish Ministry of Education. A G-U is supported by Madrid Community Program for Talent Attraction. P.B. received support from BBVA (Becas Leonardo 2018, BBM-TRA-0041) and F.M. from FdF (Fondation de France; 2014_00051580 and 2016_00067080), ARC (Association pour la Recherche sur le Cancer; PJA20181208172), and GEFLUC – Les Entreprises contre le Cancer. M.A. was supported by a FdF fellowship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation

  • Ortiz-Rivero, Sara
  • Baquero, Cristina
  • Hernández-Cano, Luis
  • Roldán-Etcheverry, Juan José
  • Gutiérrez-Herrero, Sara
  • Fernández-Infante, Cristina
  • Martín-Granado, Víctor
  • Anguita, Eduardo
  • Pereda, José M. de
  • Porras, Almudena
  • Guerrero Arroyo, María del Carmen
[Background]: Megakaryopoiesis allows platelet formation, which is necessary for coagulation, also playing an important role in different pathologies. However, this process remains to be fully characterized. C3G, an activator of Rap1 GTPases, is involved in platelet activation and regulates several differentiation processes. [Methods]: We evaluated C3G function in megakaryopoiesis using transgenic mouse models where C3G and C3GΔCat (mutant lacking the GEF domain) transgenes are expressed exclusively in megakaryocytes and platelets. In addition, we used different clones of K562, HEL and DAMI cell lines with overexpression or silencing of C3G or GATA-1. [Results]: We found that C3G participates in the differentiation of immature hematopoietic cells to megakaryocytes. Accordingly, bone marrow cells from transgenic C3G, but not those from transgenic C3GΔCat mice, showed increased expression of the differentiation markers CD41 and CD61, upon thrombopoietin treatment. Furthermore, C3G overexpression increased the number of CD41+ megakaryocytes with high DNA content. These results are supported by data obtained in the different models of megakaryocytic cell lines. In addition, it was uncovered GATA-1 as a positive regulator of C3G expression. Moreover, C3G transgenic megakaryocytes from fresh bone marrow explants showed increased migration from the osteoblastic to the vascular niche and an enhanced ability to form proplatelets. Although the transgenic expression of C3G in platelets did not alter basal platelet counts, it did increase slightly those induced by TPO injection in vivo. Moreover, platelet C3G induced adipogenesis in the bone marrow under pathological conditions. [Conclusions]: All these data indicate that C3G plays a significant role in different steps of megakaryopoiesis, acting through a mechanism dependent on its GEF activity., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness [SAF2013–48210-C2–1-R and SAF2016–76588-C2–2-R to CG, SAF2013–48210-C2–2-R and SAF2016–76588-C2–1-R to AP], and by two grants from the Council of Education of Junta de Castilla y León, Spain [SA157A12–1 and SA017U16 to CG]. All funding was cosponsored by the European FEDER Program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contribution of c3g and other gefs to liver cancer development and progression

  • Porras, Almudena
  • Sequera, Celia
  • Bragado, Paloma
  • Gutiérrez-Uzquiza, Álvaro
  • Guerrero Arroyo, María del Carmen
© The Author(s) 2021., Primary liver cancers constitute the fourth leading cause of cancer mortality worldwide, due to their high morbidity, late diagnosis and lack of effective treatments. Hepatocellular carcinoma (HCC) represents 80% and cholangiocarcinoma (CCA) 15% of liver cancers. Several genetic and epigenetic gene alterations (e.g., TERT, TP53 or CTNNB1) are HCC drivers, although many additional gene alterations contribute to HCC initiation and/or progression. Rho and Ras GTPases have been widely implicated in tumorigenesis and their activators (GEFs) have recently emerged as putative key players in liver cancer. The Ras GEF, C3G (RAPGEF1), a GEF mainly for Rap proteins, has recently been uncovered as a relevant gene in HCC. Its upregulation promotes tumor growth, although a decrease in C3G levels favors migration/invasion and lung metastasis. Rap1A/1B/2A/2B are overexpressed in HCC tumors, but their effects are controversial and not equivalent to those of C3G. The C3G partner, CRKL, is also overexpressed in HCC, promoting proliferation, migration and invasion. Various Rho GEFs are also deregulated in liver cancer. Tiam1 and Tiam2 expression is upregulated in HCC, promoting proliferation, migration and metastasis. In addition, ARHGEF-10L/9/19/39 are overexpressed in HCC tumors, facilitating migration, invasion, metastasis and proliferation. Another Rho GEF, Vav2, is also involved in metastasis. Little is known about the participation of these GEFs and GTPases in CCA. However, analysis of cancer databases uncovered deregulations or genetic alterations in several of these genes, in both CCA and HCC. Hence, GEFs function appear essential for liver homeostasis, although future studies are needed to define their precise function in liver cancer., The work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2016-76588-C2-1-R and PID2019-104143RB-C22 to Porras A; and SAF2016-76588-C2-2-R and PID2019-104143RB-C21 to Guerrero G and PID2019-104991RB-I00 to Bragado P), and by two grants from the Council of Education of Junta de Castilla y León, Spain (SA017U16 and SA078P20 to Guerrero C). All funding was cosponsored by the European FEDER Program. Sequera C was supported by a fellowship from Complutense University from Madrid. Gutierrez-Uzquiza A is supported by Madrid Community Program for Talent Attraction (MRF 2017-T1/BMD-5468). Bragado P received support from BBVA (Becas Leonardo 2018, BBM-TRA-0041).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

  • Palao, Nerea
  • Sequera, Celia
  • Cuesta, Ángel M.
  • Baquero, Cristina
  • Bragado, Paloma
  • Gutiérrez-Uzquiza, Álvaro
  • Sánchez, Aranzazu
  • Guerrero Arroyo, María del Carmen
  • Porras, Almudena
Previous data indicate that C3G (RapGEF1) main isoform is highly expressed in liver progenitor cells (or oval cells) compared to adult mature hepatocytes, suggesting it may play an important role in oval cell biology. Hence, we have explored C3G function in the regulation of oval cell properties by permanent gene silencing using shRNAs. We found that C3G knock-down enhanced migratory and invasive ability of oval cells by promoting a partial epithelial to mesenchymal transition (EMT). This is likely mediated by upregulation of mRNA expression of the EMT-inducing transcription factors, Snail1, Zeb1 and Zeb2, induced in C3G-silenced oval cells. This EMT is associated to a higher expression of the stemness markers, CD133 and CD44. Moreover, C3G down-regulation increased oval cells clonogenic capacity by enhancing cell scattering. However, C3G knock-down did not impair oval cell differentiation into hepatocyte lineage. Mechanistic studies revealed that HGF/MET signaling and its pro-invasive activity was impaired in oval cells with low levels of C3G, while TGF-β signaling was increased. Altogether, these data suggest that C3G might be tightly regulated to ensure liver repair in chronic liver diseases such as non-alcoholic steatohepatitis. Hence, reduced C3G levels could facilitate oval cell expansion, after the proliferation peak, by enhancing migration., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness [SAF2013-48210-C2-2-R, SAF2016-76588-C2-1-R and PID2019-104143RB-C22 to AP funded by MCIN/ AEI/ 10.13039/501100011033; SAF2013-48210-C2-1-R, SAF2016-76588-C2-2-R and PID2019-104143RB-C21 to CG; PID2019-104991RB-I00 to PB, PID2020-117650RA-I00 to A G-U and RTI2018-099098-B-100 to AS], and by two grants from the Council of Education of Junta de Castilla y León, Spain [SA157A12-1 and SA017U16 to CG]. All funding was cosponsored by the European FEDER Program. NP is a recipient of FPU fellowship from Spanish Ministry of Education. CS was supported by a fellowship from Complutense University from Madrid and CB by PID2019-104143RB-C22 contract and “Program for young employment from Madrid Community (PEJD-2019-PRE_BMD-14083). A G-U is supported by Madrid Community Program for Talent Attraction (MRF 2017-T1/BMD-5468).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New functions of C3G in platelet biology: Contribution to ischemia-induced angiogenesis, tumor metastasis and TPO clearance

  • Hernández-Cano, Luis
  • Fernández-Infante, Cristina
  • Herranz, Óscar
  • Berrocal, Pablo
  • Lozano, Francisco S.
  • Sánchez-Martin, Manuel Adolfo
  • Porras, Almudena
  • Guerrero Arroyo, María del Carmen
C3G is a Rap1 guanine nucleotide exchange factor that controls platelet activation, aggregation, and the release of α-granule content. Transgenic expression of C3G in platelets produces a net proangiogenic secretome through the retention of thrombospondin-1. In a physiological context, C3G also promotes megakaryocyte maturation and proplatelet formation, but without affecting mature platelet production. The aim of this work is to investigate whether C3G is involved in pathological megakaryopoiesis, as well as its specific role in platelet mediated angiogenesis and tumor metastasis. Using megakaryocyte-specific C3G knockout and transgenic mouse models, we found that both C3G overexpression and deletion promoted platelet-mediated angiogenesis, induced by tumor cell implantation or hindlimb ischemia, through differential release of proangiogenic and antiangiogenic factors. However, only C3G deletion resulted in a higher recruitment of hemangiocytes from the bone marrow. In addition, C3G null expression enhanced thrombopoietin (TPO)-induced platelet production, associated with reduced TPO plasma levels. Moreover, after 5-fluorouracil-induced platelet depletion and rebound, C3G knockout mice showed a defective return to homeostatic platelet levels, indicating impaired platelet turnover. Mechanistically, C3G promotes c-Mpl ubiquitination by inducing Src-mediated c-Cbl phosphorylation and participates in c-Mpl degradation via the proteasome and lysosome systems, affecting TPO internalization. We also unveiled a positive role of platelet C3G in tumor cell-induced platelet aggregation, which facilitated metastatic cell homing and adhesion. Overall, these findings revealed that C3G plays a crucial role in platelet-mediated angiogenesis and metastasis, as well as in platelet level modulation in response to pathogenic stimuli., This publication is part of the R + D + i projects SAF 2016-76588-C2-2-R and PID 2019-104143RB-C21 (CG), SAF 2016-76588-C2-1-R and PID 2019-104143RB-C22 (AP) funded by MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe”, and of the projects SA017U16 and SA078P20 (CG) funded by the Council of Education of Junta de Castilla y León, Spain and ERDF “A way of making Europe”. LH-C and CF-I are recipients of fellowships from the Council of Education of Junta de Castilla y León, Spain. ÓH is recipient of a FPU fellowship from The Spanish Ministry of Education. The authors’ institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-funded by Junta de Castilla y León and ERDF (CLC-2017-01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction

  • Fernández-Infante, Cristina
  • Hernández-Cano, Luis
  • Herranz, Óscar
  • Berrocal, Pablo
  • Sicilia-Navarro, Carmen
  • González-Porras, José R.
  • Bastida, José María
  • Porras, Almudena
  • Guerrero Arroyo, María del Carmen
C3G is a Rap1 GEF that plays a pivotal role in platelet-mediated processes such as angiogenesis, tumor growth, and metastasis by modulating the platelet secretome. Here, we explore the mechanisms through which C3G governs platelet secretion. For this, we utilized animal models featuring either overexpression or deletion of C3G in platelets, as well as PC12 cell clones expressing C3G mutants. We found that C3G specifically regulates α-granule secretion via PKCδ, but it does not affect δ-granules or lysosomes. C3G activated RalA through a GEF-dependent mechanism, facilitating vesicle docking, while interfering with the formation of the trans-SNARE complex, thereby restricting vesicle fusion. Furthermore, C3G promotes the formation of lamellipodia during platelet spreading on specific substrates by enhancing actin polymerization via Src and Rac1-Arp2/3 pathways, but not Rap1. Consequently, C3G deletion in platelets favored kiss-and-run exocytosis. C3G also controlled granule secretion in PC12 cells, including pore formation. Additionally, C3G-deficient platelets exhibited reduced phosphatidylserine exposure, resulting in decreased thrombin generation, which along with defective actin polymerization and spreading, led to impaired clot retraction. In summary, platelet C3G plays a dual role by facilitating platelet spreading and clot retraction through the promotion of outside-in signaling while concurrently downregulating α-granule secretion by restricting granule fusion., his work was supported by Grants SAF2016-76588-C2-2-R and PID2019-104143RB-C21 (CG), SAF2016-76588-C2-1-R and PID2019-104143RB-C22 (AP) funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and ERDF “A way of making Europe”, and by grants SA017U16 and SA078P20 (CG) funded by the Council of Education of Junta de Castilla y León, Spain and ERDF “A way of making Europe”. CF-I, LH-C and PB are recipients of fellowships from the Council of Education of Junta de Castilla y León, Spain, and The Social European Funding. ÓH is recipient of a FPU fellowship from the Spanish Ministry of Education. The authors’ institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-funded by Junta de Castilla y León and ERDF (CLC-2017-01) and by the Scientific Foundation of the Spanish Association Against Cancer (Programa Excelencia 2022 EPAEC222641CICS)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells.

  • Herranz, Óscar
  • Rodrigo-Faus, María
  • Jauregui, Patricia
  • Morgner, Stephanie
  • Rubio, Ignacio
  • Guerrero, Carmen
  • Porras, Almudena
  • Gutiérrez Uzquiza, Álvaro
  • Manzano Figueroa, Sara
  • Bragado Domingo, Paloma
  • Sequera Hurtado, Celia
Glioblastoma (GBM) is the most aggressive tumor from the central nervous system (CNS). The current lack of efficient therapies makes essential to find new treatment strategies. C3G, a guanine nucleotide exchange factor for some Ras proteins, plays a dual role in cancer, but its function in GBM remains unknown. Database analyses revealed a reduced C3G mRNA expression in GBM patient samples. C3G protein levels were also decreased in a panel of human GBM cell lines as compared to astrocytes. Based on this, we characterized C3G function in GBM using in vitro and in vivo human GBM models. We report here that C3G downregulation promoted the acquisition of a more mesenchymal phenotype that enhanced the migratory and invasive capacity of GBM cells. This facilitates foci formation in anchorage-dependent and -independent growth assays and the generation of larger tumors in xenografts and chick chorioallantoic membrane (CAM) assays, but with a lower cell density, as proliferation was reduced. Mechanistically, C3G knock-down impairs EGFR signaling by reducing cell surface EGFR through recycling inhibition, while upregulating the activation of several other receptor tyrosine kinases (RTKs) that might promote invasion. In particular, FGF2, likely acting through FGFR1, promoted invasion of C3G-silenced GBM cells. Moreover, ERKs mediate this invasiveness, both in response to FGF2- and serum-induced chemoattraction. In conclusion, our data show the distinct dependency of GBM tumors on C3G for EGF/EGFR signaling versus other RTKs, suggesting that assessing C3G levels may discriminate GBM patient responders to different RTK inhibition protocols. Hence, patients with a low C3G expression might not respond to EGFR inhibitors.